ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announced the signing of $10 million Series B Plus strategic financing. The round of financing will be exclusively funded by Shanghai Healthcare Capital (SHC), managed by SIIC Capital, where Shanghai Pharma is one of the founding…